(MENAFN) Hikma Pharmaceuticals plc, the fast growing multinational pharmaceutical group, said it will acquire 98.09 percent of the share capital of EIMC United Pharmaceuticals (EUP).
Egypt's EUP is a pharmaceutical manufacturing company specializing in oncology products. The acquisition of EUP strengthens Hikma's position in the large and fast growing Egyptian market.
Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based mainly in MENA region. In 2014, it achieved revenues of USD1.48 billion and profit of USD299 million.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.